$0.04
+0.00%Price chart
Aug 14Aug 21Aug 27Sep 9Sep 17Sep 29Oct 7Oct 15
Key dataOct 15, 2026
Open$0.04
From 52W high−88.51%
Volume213.00
Market cap$1.08M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 15, 2026
Open
$0.04
From 52W high
−88.51%
Volume
213.00
Market cap
$1.08M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.0x
P/E (TTM)
—
RSI (14)
46.4
MomentumView details →
1D Return
+0.00%
YTD Return
+14.29%
SummaryUpdated Jun 1, 2026
Liminatus Pharma, Inc. (NASDAQ:LIMNW) is a clinical-stage immuno-oncology biotechnology company founded and based in La Palma, California. The company went public in April 2025 and focuses on developing novel cancer therapies that harness the body's immune system to fight cancer. As a pre-revenue biotechnology company, Liminatus is in the early stages of drug development, working to advance its therapeutic candidates through clinical trials with the ultimate goal of bringing new cancer treatments to market.
Similar companies
Latest newsMore news →
Liminatus Pharma regained compliance with Nasdaq's $1 minimum bid price requirement after effecting a 1-for-50 reverse stock split on August 20, 2026.21d agoLiminatus Pharma, Inc. announced a 1-for-50 reverse stock split of its common stock, approved by its board and stockholders at the 2026 Annual Meeting held on August 3, 2026.62d agoLiminatus Pharma, Inc. received a notice from NASDAQ on 2026-08-12 that it is not in compliance with Listing Rule 5550(a)(2) regarding minimum bid price, and plans to implement a 1-for-50 reverse stock split.63d ago